ANDRIEN BRUCE A JR,SHERIDAN DOUGLAS L,TAMBURINI PAUL P
申请号：
IN201617027515
公开号：
IN201617027515A
申请日:
2016.08.11
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
The disclosure provides antibodies that are useful for among other things inhibiting terminal complement (e.g. the assembly and/or activity of the C5b 9 TCC) and C5a anaphylatoxin mediated inflammation and thus treating complement associated disorders. The antibodies have a number of improved properties relative to eculizumab including e.g. increased serum half life in a human.
